ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2023
The Role of Novel Antibiotics in the Management of Diabetic Foot Infection.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of diabetic foot infections: pathogenesis, diagnosis, and management strategies.Frontiers in clinical diabetes and healthcare · 2024Pooled it
- Mild photothermal-responsive hydrogel with HBioactive materials · 2026Article
- Potential of phage therapy for the treatment of diabetic foot infections.Folia microbiologica · 2026Review
- Lignin-Based Nanoparticles Loaded with Essential Oils: Potential for Diabetic Foot Infection Management.ACS materials Au · 2026Article
- Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.Antibiotics (Basel, Switzerland) · 2026Review
- Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review).Experimental and therapeutic medicine · 2026Review
- Feeding the invaders: how metabolic imbalance shapes infection and biofilm development.FEMS microbiology reviews · 2026Review
- Cefiderocol as a Successful Therapy for Osteomyelitis Due to XDRAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study.Journal of clinical medicine · 2025Article
- Diabetes Mellitus and Infectious Diseases: Current Evidence and Clinical Implications.Diabetes & metabolism journal · 2025Review
- From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.International journal of molecular sciences · 2025Review
- Smart self-healing hydrogel wound dressings for diabetic wound treatment.Nanomedicine (London, England) · 2025Review
- Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance.Acta diabetologica · 2025Review
- Diabetes potentiates the emergence and expansion of antibiotic resistance.Science advances · 2025Article
- Triple threat: how diabetes results in worsened bacterial infections.Infection and immunity · 2024Review
- Advanced multifunctional hydrogels for diabetic foot ulcer healing: Active substances and biological functions.Journal of diabetes · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot infection is a frequent and potentially life-threatening complication of diabetes mellitus. Antibiotic treatment is the cornerstone of management of diabetic foot infection but the rising prevalence of antibiotic resistance has resulted in increasing rates of treatment failure. In this context, the development of several novel antibiotics might represent a useful tool in severe diabetic foot infections caused by multidrug-resistant bacteria. In the present review, we summarize the safety and efficacy of novel antibiotics in patients with diabetic foot infection. Relevant data are limited, and randomized controlled studies that evaluated the role of these agents in this field are lacking. Until more robust data are available, cefiderocol and dalbavancin, which have been studied more extensively in patients with bone infections, might be attractive options in carefully selected patients with severe diabetic foot infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.